RSC Pharmaceutics最新文献

{"title":"Biogenic chitosan anchored Cu2O/ZnO nanocomposite: unlocking synergy for drug delivery, antineoplastic action, and wound repair","authors":"Manojna R. Nayak, Ravindra R. Kamble, Lokesh Bheemayya, Vishwa B. Nadoni, Amruta Patri, Mallika Wali, Arun K. Shettar, Joy H. Hoskeri, Rangappa S. Keri and Ashok M. Sajjan","doi":"10.1039/D5PM00392J","DOIUrl":"https://doi.org/10.1039/D5PM00392J","url":null,"abstract":"<p >The clinical efficacy of many chemotherapeutic agents is often limited by inefficient drug delivery, poor selectivity toward cancer cells, and insufficient support for tissue regeneration. To address these challenges, we report the green synthesis of a multifunctional chitosan-anchored Cu<small>₂</small>O/ZnO nanocomposite (CS-Cu<small>₂</small>O/ZnO NC) using water calyx fluid (WCF) extracted from <em>Spathodea campanulata</em> flower buds as a natural reducing and stabilizing agent. Structural and physicochemical characterization using X-ray diffraction confirmed the crystalline phases of Cu<small>₂</small>O and ZnO, while UV-Vis spectroscopy showed characteristic absorption in the 270–320 nm region indicating nanoparticle formation. FTIR analysis verified the successful integration of chitosan and phytochemical functional groups with metal oxides. Transmission electron microscopy revealed quasi-spherical nanoparticles uniformly distributed within the polymer matrix with an average particle size of 20–40 nm, whereas dynamic light scattering showed a hydrodynamic diameter of ∼89.3 nm with a zeta potential of −29.4 mV, confirming good colloidal stability. The nanocomposite was employed as a carrier for cisplatin and exhibited high drug loading efficiency with a biphasic release profile, achieving 94.88% cumulative drug release over 72 h. <em>In vitro</em> cytotoxicity studies demonstrated enhanced anticancer activity against A375 skin cancer cells (IC<small>₅₀</small> = 29.84 µg mL<small>⁻¹</small>) with comparatively lower toxicity toward L929 fibroblast cells. Furthermore, scratch wound healing assays revealed significant fibroblast cell migration and accelerated wound closure within 24 h, highlighting the regenerative potential of the nanocomposite. Overall, the developed green-synthesized CS-Cu<small>₂</small>O/ZnO nanocomposite represents a sustainable multifunctional platform for controlled drug delivery, cancer therapy, and wound healing applications.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 3","pages":" 778-798"},"PeriodicalIF":0.0,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00392j?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148011755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vivo translation of a dual-stimuli-responsive drug carrier based on mesoporous silica nanoparticles for the co-delivery of camptothecin and 5-fluorouracil","authors":"Debatrayee Dasgupta, Sonal Thakore, Anjali Patel and Sriram Seshadri","doi":"10.1039/D5PM00390C","DOIUrl":"https://doi.org/10.1039/D5PM00390C","url":null,"abstract":"<p >With the advent of nanotechnology, combined drug therapies employing dual-drug delivery provide an efficient way to overcome the drawbacks of conventional chemotherapy, such as lack of specificity, multidrug resistance and low aqueous solubility. Herein, a dual-drug delivery system based on mesoporous silica nanoparticles (MSNs) was developed to target tumours with the dual-responsive co-delivery of two anticancer drugs, camptothecin (CPT) and 5-fluorouracil (5-FU), in a sequential manner. The mesopores were loaded with CPT, and subsequently, a pegylated-biotin polymer was used to coat them. The disulphide link and acid group present in the polymer contribute to the stimuli-triggered release of the drugs. Since cancer cells need biotin to continue proliferating, it functions as a targeting ligand. Mathematical modelling studies revealed that the drug-release kinetics followed a diffusion mechanism for both the hydrophobic and hydrophilic drugs. Beyond <em>in vitro</em> release and cytotoxicity assays, extensive <em>in vivo</em> biological evaluations, including liver function markers, serum biochemistry and histopathological examinations, demonstrated pronounced tumour suppression with reduced hepatic toxicity. The nanocarrier downregulated key tumour biomarkers, effectively lowered serum transaminases and restored normal liver architecture. Collectively, these findings affirm the translational potential of this smart dual-drug delivery platform for cancer therapy.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 3","pages":" 738-748"},"PeriodicalIF":0.0,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00390c?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148011752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Enhancing the bioavailability of sparingly-soluble drugs by expandable, solid-solution fibrous dosage forms","authors":"Aron H. Blaesi, Henning Richter and Nannaji Saka","doi":"10.1039/D6PM90005D","DOIUrl":"https://doi.org/10.1039/D6PM90005D","url":null,"abstract":"<p >Correction for ‘Enhancing the bioavailability of sparingly-soluble drugs by expandable, solid-solution fibrous dosage forms’ by Aron H. Blaesi <em>et al.</em>, <em>RSC Pharm.</em>, 2026, <strong>3</strong>, 88–102, https://doi.org/10.1039/D5PM00195A.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 3","pages":" 820-820"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d6pm90005d?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148011758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Merged in silico–in vitro validations of atenolol and amlodipine besylate with excipient interactions for the design of solid oral dosage forms","authors":"Gaurav Awasthi and Subham Banerjee","doi":"10.1039/D6PM00014B","DOIUrl":"https://doi.org/10.1039/D6PM00014B","url":null,"abstract":"<p >Early understanding and estimation of interactions between drugs and excipients is a crucial step in preformulation studies. <em>In silico</em> studies utilising computational methods were followed by <em>in vitro</em> studies and analytical validation to identify stable excipients (SmartEx and Ludipress) for the development of solid oral dosage forms. <em>In silico</em> studies were conducted using the FormulationDE machine learning tool, which utilises artificial intelligence to interpret input data. FormulationDE can predict compatibility outcomes based on functional groups using SHAP (Shapley Additive explanations) force plots. <em>In vitro</em> studies, including isothermal stress testing methods, ATR-FTIR, DSC and drug stability profiles, were conducted to assess the potential for DEIs under long-term storage and physiological conditions. These studies were demonstrated, and samples were analysed using high-performance liquid chromatography to quantify the percentage of drug degradation over time. The <em>in silico</em> studies showed that ATN was compatible with lactose and mannitol, whereas AMB was incompatible with both. The <em>in vitro</em> IST results showed that ATN was compatible with SmartEx, whereas AMB was incompatible with Ludipress and SmartEx. Drug stability profiles were obtained under gastric pH (1.2) and incubation at 37 °C for four hours to evaluate the resilience of the drugs under physiological conditions and to mimic the gastric environment. The drug stability profiles showed that AMB was unstable and ATN was stable under the gastric physiological conditions. This article highlights the importance of integrating <em>in silico</em> with <em>in vitro</em> experimental techniques in preformulation to minimise risk during later stages of formulation development. The results of various studies will guide the future development of ATN-based solid oral dosage forms using SmartEx QD 100 thermoplastic excipients.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 3","pages":" 768-777"},"PeriodicalIF":0.0,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d6pm00014b?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148011754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing the performance of granisetron HCl orodispersible tablets using co-processed MCC-mannitol excipients: a direct compression approach","authors":"Shazia Naseem Chaudhry and Atiq Ur Rahman","doi":"10.1039/D5PM00276A","DOIUrl":"https://doi.org/10.1039/D5PM00276A","url":null,"abstract":"<p >Orodispersible tablets (ODTs) are favored for their rapid disintegration in the mouth without the need for water, thereby improving patient compliance, particularly in dysphagic, geriatric, and oncology patients. Advanced manufacturing technologies like Orasolv®, Durasolv®, and Zydis® offer unique benefits but are generally associated with high costs and intricate processes. Common manufacturing approaches include molding, freeze-drying, and direct compression, with the latter being the most economical and industrially practical method. The present study aimed to develop granisetron HCl ODTs using a laboratory-prepared co-processed excipient system composed of microcrystalline cellulose (MCC) and mannitol. The system was developed by combining the excipients at the sub-particle level to enhance flowability and compressibility, rather than relying on commercially available multifunctional excipients. The performance of this co-processed MCC–mannitol system was systematically compared with that of the corresponding physical mixtures. Granisetron HCl is a 5-HT3 receptor antagonist commonly prescribed to manage nausea and vomiting induced by chemotherapy. It is well-suited for ODTs due to its low dosage requirements and water solubility. In the formulations, microcrystalline cellulose and mannitol were used as bulking agents and sodium starch glycolate (SSG) and crospovidone (CP) as superdisintegrants. The performance of co-processed excipients was compared with that of physical mixtures. Precompression parameters, including the angle of repose and compressibility index, along with post-compression characteristics such as wetting time, water absorption ratio, disintegration time, and <em>in vitro</em> drug release, were evaluated. Among the tested formulations, formulation F7 containing 4% crospovidone and co-processed MCC–mannitol exhibited the most favorable performance, with a rapid disintegration time of 10 ± 0.12 s and 98.14% ± 0.25% drug release within 180 s. Comparative evaluation demonstrated that the co-processed excipient system provided improved powder flow and tablet performance relative to the physical mixtures. These findings indicate that at the sub-particle level, the co-processing of conventional excipients can be an effective and practical strategy to enhance the ODT performance using a cost-effective direct compression approach.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 3","pages":" 809-819"},"PeriodicalIF":0.0,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00276a?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148011757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polymer-lipid hybrid nanoparticles co-encapsulating fucoxanthin and carbon dots for targeted anti-inflammatory therapy in Alzheimer's disease","authors":"J. Horacio Silvestre-Martínez, Lorna G. Yañez-Algandar, Karina del Carmen Lugo-Ibarra and Ana B. Castro-Ceseña","doi":"10.1039/D6PM00008H","DOIUrl":"https://doi.org/10.1039/D6PM00008H","url":null,"abstract":"<p >Alzheimer's disease (AD) is a long-term brain disorder characterized by the buildup of proteins like amyloid-beta (Aβ) and Tau. This disease process can start up to 20 years before symptoms such as memory loss, language problems, changes in personality, and eventually dementia appear. Currently, AD has no cure, and available treatments only ease symptoms, making it a major global health concern. Developing new therapies is urgently needed. Nanomedicine presents promising solutions, especially for overcoming challenges like delivering drugs across the blood–brain barrier (BBB). In this study, we explored polymer-lipid hybrid nanoparticles (NPs) decorated with transferrin (Tf) to help them cross the BBB. These NPs were loaded with carbon dots (CDs) and fucoxanthin (Fx), which have antioxidant and anti-inflammatory qualities that may benefit neurodegenerative disease treatment. The resulting nanoparticle formulation (NPs-CDFx) had encapsulation efficiencies of 45% for Fx and 10% for CDs, with an average particle size of about 88.74 nm. The safety of these NPs was tested using an <em>in vitro</em> model with lipopolysaccharide (LPS) stimulated rat astrocytes, where high cell viability (92.18%) was observed. qPCR analysis showed that NPs-CDFx significantly lowered the expression of genes linked to neuroinflammation and disease progression, such as APP, GFAP, and S100β. To further confirm delivery, the NPs were injected into five-day-old zebrafish larvae, where confocal microscopy detected the CDs’ fluorescence in the brain, indicating successful targeted delivery across the BBB. Overall, these findings suggest that the nanoparticles can efficiently deliver therapeutic agents to the brain, reduce neuroinflammatory gene expression, and demonstrate the effectiveness of polymer-lipid hybrid nanoparticles for targeted brain drug delivery.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 3","pages":" 669-681"},"PeriodicalIF":0.0,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d6pm00008h?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148011766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kinetic modelling and in vitro release mechanism of levodopa from sporopollenin-based microcapsules in human blood plasma","authors":"Shwan Abdullah Hamad, Zhila Salam Othman, Shilan Hiwa Hama Salih and Trefa Mohammed Abdullah","doi":"10.1039/D5PM00261C","DOIUrl":"https://doi.org/10.1039/D5PM00261C","url":null,"abstract":"<p >Levodopa (LD) remains the most effective therapy for Parkinson's disease; however, its short plasma half-life necessitates frequent dosing and contributes to fluctuating drug levels and motor complications. In this study, we systematically investigated the <em>in vitro</em> release behaviour of LD from sporopollenin exine microcapsules (SECs) in a clinically relevant biological medium, human blood plasma, and applied kinetic modelling to elucidate the governing release mechanism. LD-loaded sporopollenin microcapsules (0.5 g) were prepared by vacuum-assisted, pH-triggered precipitation and incubated in human plasma at 37 °C under moderate agitation (50 rpm). Release experiments were conducted over 12 h, with sequential sampling and medium replacement to maintain constant volume and sink conditions. LD concentrations were quantified by UV-Vis spectrophotometry using validated plasma-matched calibration curves. The release profile exhibited a reproducible biphasic pattern, characterised by a rapid initial phase within the first 30 min, followed by a prolonged and stable release phase extending to 12 h. Despite low fractional release, the system rapidly established a therapeutically relevant equilibrium LD concentration in plasma, indicative of reservoir-controlled drug availability rather than depletion-driven release. Kinetic modelling demonstrated that the Higuchi model provided the best fit to the concentration-time data (<em>R</em><small>²</small> = 0.9955 ± 0.0008). In contrast, the Korsmeyer–Peppas model yielded a low release exponent (<em>n</em> = 0.209 ± 0.002), consistent with diffusion-dominated, Fickian transport. Peppas–Sahlin analysis further confirmed the predominance of diffusional mechanisms, with minimal contribution from matrix relaxation. These findings demonstrate that SECs function as stable, reservoir-type carriers that provide both rapid initial LD availability and sustained plasma concentrations under physiologically relevant conditions. This work, to our knowledge, represents the first detailed kinetic analysis of LD release from SECs in human blood plasma and highlights the potential of this natural biopolymer as a bio-regulated platform for improved LD delivery in Parkinson's disease.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 3","pages":" 799-808"},"PeriodicalIF":0.0,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00261c?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148011756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Needle-free transdermal delivery of mRNA vaccine with ionic liquid crystals and effective tumor growth inhibition","authors":"Tomohiro Higashi, Keisuke Tanaka, Kiyohiro Toyofuku, Rie Wakabayashi, Yoshirou Kawaguchi, Noriho Kamiya and Masahiro Goto","doi":"10.1039/D5PM00327J","DOIUrl":"https://doi.org/10.1039/D5PM00327J","url":null,"abstract":"<p >mRNA vaccines have emerged as a promising therapeutic option based on their ability to elicit a strong immune response, the reduced risk of genomic integration, and the potential to produce various vaccine candidates using the same manufacturing process. However, current mRNA vaccines primarily rely on injection-based administration, which is an invasive procedure that requires a healthcare professional. To address these limitations, transdermal delivery has been proposed as a non-invasive alternative. However, the stratum corneum (SC) acts as a formidable barrier to biopharmaceuticals penetration, necessitating innovative approaches for effective transdermal vaccination. In this study, we developed a novel ionic liquid crystal (ILC), which was formulated from a lyotropic liquid crystal (LLC) using ionic liquids (ILs) with amphiphilic molecular properties. ILC formulations were prepared by mixing ILs with ultrapure water and demonstrated optimal viscoelastic properties for transdermal application. <em>In vitro</em> skin permeation assays revealed the superior mRNA penetration of ILC formulations compared with aqueous mRNA solutions. Furthermore, <em>in vivo</em> evaluation using a tumor-bearing mouse model revealed that transdermal mRNA delivery <em>via</em> ILCs significantly suppressed tumor growth and promoted CD8+ T-cell infiltration into tumor tissues, indicating a potent antitumor effect. These findings highlight the potential of ILC-based transdermal mRNA delivery as a promising strategy for the development of next-generation mRNA vaccine administration methods.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 3","pages":" 659-668"},"PeriodicalIF":0.0,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00327j?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148011765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"QbD-optimized HA–Pluronic nanomicelles for the targeted repurposing of tofacitinib in breast cancer","authors":"Suchita Waghmare, Rohini Palekar, Pratiksha Bramhe, Nilesh Rarokar and Pramod Khedekar","doi":"10.1039/D5PM00391A","DOIUrl":"https://doi.org/10.1039/D5PM00391A","url":null,"abstract":"<p >Tofacitinib, a Janus kinase (JAK) inhibitor clinically approved for rheumatoid arthritis, holds significant potential for repurposing in breast cancer therapy due to its ability to suppress the oncogenic STAT3 signaling pathway; however, its therapeutic application is hindered by poor aqueous solubility, rapid systemic clearance, and non-specific distribution. To address these limitations, this study aimed to develop hyaluronic acid (HA)-decorated Pluronic F127 (PF127) micelles to enhance the solubility, bioavailability, and targeted delivery of Tofacitinib to CD44-overexpressing breast cancer cells. A Quality by Design (QbD) approach utilizing a Box–Behnken design (BBD) was employed to systematically optimize critical process parameters—drug-to-polymer ratio, polymer concentration, and stirring temperature—to minimize particle size and polydispersity index (PDI) while maximizing entrapment efficiency. The optimized micelles exhibited a uniform particle size of 159.2 ± 3.8 nm, a narrow PDI of 0.221, a high entrapment efficiency of 91.14%, and a negative zeta potential of −24.6 mV, ensuring colloidal stability. <em>In vitro</em> evaluation demonstrated a sustained, diffusion-controlled drug release profile and significantly enhanced cytotoxicity against MCF-7 breast cancer cells (IC<small>₅₀</small> 14.2 µg mL<small>⁻¹</small>) compared to the free drug (IC<small>₅₀</small> 46.8 µg mL<small>⁻¹</small>), attributed to CD44-mediated cellular uptake. Furthermore, <em>in vivo</em> pharmacokinetic analysis in Wistar rats revealed a 4.3-fold increase in oral bioavailability and a prolonged elimination half-life compared to free Tofacitinib, while histopathological studies confirmed the formulation's biocompatibility and safety in major organs. These findings collectively support the viability of the QbD-optimized HA–PF127 micellar system as a promising nanocarrier platform for the effective oral repurposing of Tofacitinib in breast cancer treatment.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 3","pages":" 749-767"},"PeriodicalIF":0.0,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00391a?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148011753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"nor-MC3 and nor-KC2: cationic ionizable lipids for the delivery of therapeutic nucleic acids","authors":"Deaglan Arnold, Nagavenkata Durga Prasad Atmuri, Fariba Saadati, Ardalan Nabi, Daniel Z. Kurek, Anthony Tam, Taniya Adak, Dominik Witzigmann, Glenn Sammis, Pieter R. Cullis, Jayesh Kulkarni and Marco A. Ciufolini","doi":"10.1039/D5PM00350D","DOIUrl":"https://doi.org/10.1039/D5PM00350D","url":null,"abstract":"<p > <em>nor</em>-MC3 and <em>nor</em>-KC2, analogues of D-Lin-MC3-DMA (cationic ionizable lipid in Onpattro®) and D-Lin-KC2-DMA (valuable research tool) wherein C<small>₁₇</small> lipophilic chains replace C<small>₁₈</small> ones, are at least as efficacious as the originals, but more economical and safer to produce.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 3","pages":" 654-658"},"PeriodicalIF":0.0,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00350d?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148011764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}